Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 20923031)

1.

Androgen deprivation therapy: a survival benefit or detriment in men with high-risk prostate cancer?

Fang LC, Merrick GS, Wallner KE.

Oncology (Williston Park). 2010 Aug;24(9):790-6, 798. Review.

2.

Synergistic action of image-guided radiotherapy and androgen deprivation therapy.

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG.

Nat Rev Urol. 2015 Apr;12(4):193-204. doi: 10.1038/nrurol.2015.50. Epub 2015 Mar 24. Review.

PMID:
25800395
3.

Prostate cancer: 2-year ADT improves survival in patients receiving high-dose radiotherapy.

Thoma C.

Nat Rev Urol. 2015 Apr;12(4):181. doi: 10.1038/nrurol.2015.43. Epub 2015 Mar 10. No abstract available.

PMID:
25753100
4.

The double-edged sword of ADT: emerging evidence of cardiovascular, pulmonary, and renal risks.

Anantharaman A, Friedlander TW.

Oncology (Williston Park). 2015 Jan;29(1):67-8. No abstract available.

5.

Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era.

D'Angelillo RM, Franco P, De Bari B, Fiorentino A, Arcangeli S, Alongi F.

Crit Rev Oncol Hematol. 2015 Feb;93(2):136-48. doi: 10.1016/j.critrevonc.2014.10.003. Epub 2014 Oct 17.

PMID:
25459667
6.

Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis.

Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, Bianco BA, Chang P, Pompeo AC, Tobias-Machado M.

World J Urol. 2014 Nov 12. [Epub ahead of print]

PMID:
25387877
7.

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies.

Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, Tian H, Li P, Niu Y.

PLoS One. 2014 Sep 29;9(9):e107516. doi: 10.1371/journal.pone.0107516. eCollection 2014.

8.

The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer.

Edelman S, Butler J, Hershatter BW, Khan MK.

Clin Genitourin Cancer. 2014 Dec;12(6):399-407. doi: 10.1016/j.clgc.2014.07.009. Epub 2014 Aug 2.

PMID:
25193364
9.

Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies.

Zapatero A, González San Segundo C, Boladeras A, Gómez Caamaño A, López Torrecilla J, Maldonado X.

Clin Transl Oncol. 2015 Mar;17(3):223-9. doi: 10.1007/s12094-014-1217-3. Epub 2014 Sep 3.

PMID:
25183050
10.

The status of surgery in the management of high-risk prostate cancer.

Bach C, Pisipati S, Daneshwar D, Wright M, Rowe E, Gillatt D, Persad R, Koupparis A.

Nat Rev Urol. 2014 Jun;11(6):342-51. doi: 10.1038/nrurol.2014.100. Epub 2014 May 13. Review.

PMID:
24818848
11.

Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice.

Dason S, Allard CB, Wang JG, Hoogenes J, Shayegan B.

Can J Urol. 2014 Apr;21(2 Supp 1):28-36. Review.

12.

Patterns of androgen deprivation therapies among men diagnosed with localised prostate cancer: a population-based study.

Lycken M, Garmo H, Adolfsson J, Stattin P, Holmberg L, Bill-Axelson A.

Eur J Cancer. 2014 Jul;50(10):1789-98. doi: 10.1016/j.ejca.2014.03.279. Epub 2014 Apr 12.

PMID:
24736041
14.

Improving outcomes in high-risk prostate cancer with radiotherapy.

Polkinghorn WR, Zelefsky MJ.

Rep Pract Oncol Radiother. 2013 Nov 11;18(6):333-7. doi: 10.1016/j.rpor.2013.10.006. Review.

15.

Hyaluronan-mediated motility receptor (RHAMM) immunohistochemical expression and androgen deprivation in normal peritumoral, hyperplasic and neoplastic prostate tissue.

Korkes F, de Castro MG, de Cassio Zequi S, Nardi L, Del Giglio A, de Lima Pompeo AC.

BJU Int. 2014 May;113(5):822-9. doi: 10.1111/bju.12339. Epub 2013 Oct 31.

PMID:
24053431
16.

Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients.

Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA.

Prostate Cancer Prostatic Dis. 2013 Dec;16(4):346-51. doi: 10.1038/pcan.2013.26. Epub 2013 Aug 13.

PMID:
23939133
17.

Long-term outcomes for men with high-risk prostate cancer treated definitively with external beam radiotherapy with or without androgen deprivation.

Nguyen QN, Levy LB, Lee AK, Choi SS, Frank SJ, Pugh TJ, McGuire S, Hoffman K, Kuban DA.

Cancer. 2013 Sep 15;119(18):3265-71. doi: 10.1002/cncr.28213. Epub 2013 Jun 24.

18.

The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes.

Stock RG, Buckstein M, Liu JT, Stone NN.

BJU Int. 2013 Jul;112(2):E44-50. doi: 10.1111/bju.12166. Epub 2013 Jun 14.

PMID:
23773225
19.

Assessment of endothelial dysfunction by flow-mediated dilatation in men on long-term androgen deprivation therapy for prostate cancer.

Gilbert SE, Tew GA, Bourke L, Winter EM, Rosario DJ.

Exp Physiol. 2013 Sep;98(9):1401-10. doi: 10.1113/expphysiol.2013.073353. Epub 2013 May 10.

PMID:
23666791
20.

Identification of comorbidities that place men at highest risk of death from androgen deprivation therapy before brachytherapy for prostate cancer.

Parekh A, Chen MH, D'Amico AV, Dosoretz DE, Ross R, Salenius S, Graham PL, Beckman JA, Beard CJ, Choueiri TK, Ennis RD, Hoffman KE, Hu JC, Ma J, Martin NE, Nguyen PL.

Brachytherapy. 2013 Sep-Oct;12(5):415-21. doi: 10.1016/j.brachy.2013.02.005. Epub 2013 May 4.

PMID:
23651926
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk